Indira IVF IPO: Did Tumko Meri Kasam derail the Rs 3,500 crores plan?
The intersection of Bollywood and business took an unexpected turn in 2025 when a movie reportedly disrupted Indira IVF’s much-anticipated Rs 3,500 crores initial public offering (IPO). The EQT-backed fertility clinic chain, a leader in India’s growing IVF sector, faced regulatory hurdles from the Securities and Exchange Board of India (SEBI) over the release of Tumko Meri Kasam. This Bollywood biopic, centred on Indira IVF founder Ajay Murdia, has sparked debates about the influence of media on financial markets, as per a report by Economic Times. Here’s a deep dive into how this unforeseen twist unfolded and its implications for Indira IVF’s IPO plans. The Rise of Indira IVF: A Leader in Fertility Treatments Founded in 2011 by Ajay Murdia in Udaipur, Indira IVF has grown into one of India’s most prominent fertility clinic chains. With over 150 centres and 330 specialists nationwide, the company has capitalized on the increasing demand for in-vitro fertilization (IVF) treatments. Bac...